GIBRALTAR INDUSTRIES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ROCK in the last 7 days.
No SEC Form 4 filings for $ROCK in the last 30 days.
See all $ROCK insider activity →Gibraltar Industries (ROCK) reported Q2 2026 net sales of $509.5 million, up 64.6% year over year, driven mainly by the OmniMax acquisition, plus 5% organic growth. Adjusted EBITDA rose to $88 million, and adjusted EPS was $1.11. FY2026 guidance: net sales $1.76B to $1.83B, adjusted EPS $3.65 to $4.05. Net debt was $1.2B.
Gibraltar Industries (NASDAQ: ROCK) shares rose more than 14% after the company reported Q2 results. Revenue increased about 65% to $509.5 million, helped by building products growth and the OmniMax acquisition. Adjusted net income fell about 2% to $33 million, or $1.11 per share. Gibraltar reiterated 2026 guidance for net sales of $1.76-$1.83 billion and adjusted EPS of $3.65-$4.05.
Gibraltar Industries (ROCK) shares rose about 14% after the company reported Q2 results. Revenue was $509.5M, up nearly 65% year over year, and adjusted net income was $33M or $1.11 per share. Gibraltar cited strength in building products and OmniMax integration, and reiterated 2026 guidance for $1.76B to $1.83B sales and $3.65 to $4.05 adjusted EPS.
Recent ROCK coverage spans earnings, mergers & acquisitions and financial news.
Earnings call provides fresh, decision-relevant guidance and integration progress tied to OmniMax, plus leverage and liquidity targets.
The earnings beat and raised/confirmed full-year outlook are the immediate catalysts behind the sharp move, with guidance anchoring near-term expectations.
The article ties ROCK’s sharp move to an earnings beat and raised/confirmed full-year sales and EPS outlook, suggesting near-term momentum from fundamentals.
The earnings mix is sharply negative on bottom-line but positive on revenue, with guidance reaffirmed, likely keeping near-term focus on margin trajectory.
The article discloses a fresh earnings and guidance datapoint for ROCK, with a same-day stock reaction and upside vs estimates.
alphai scores every news story that mentions ROCK with an AI model for sentiment and relevance, and aggregates insider trades from GIBRALTAR INDUSTRIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gibraltar Industries (ROCK) reported Q2 2026 net sales of $509.5 million, up 64.6% year over year, driven mainly by the OmniMax acquisition, plus 5% organic growth. Adjusted EBITDA rose to $88 million, and adjusted EPS was $1.11. FY2026 guidance: net sales $1.76B to $1.83B, adjusted EPS $3.65 to $4.05. Net debt was $1.2B.
7 min readGibraltar Industries (NASDAQ: ROCK) shares rose more than 14% after the company reported Q2 results. Revenue increased about 65% to $509.5 million, helped by building products growth and the OmniMax acquisition. Adjusted net income fell about 2% to $33 million, or $1.11 per share. Gibraltar reiterated 2026 guidance for net sales of $1.76-$1.83 billion and adjusted EPS of $3.65-$4.05.
4 min readGibraltar Industries (ROCK) shares rose about 14% after the company reported Q2 results. Revenue was $509.5M, up nearly 65% year over year, and adjusted net income was $33M or $1.11 per share. Gibraltar cited strength in building products and OmniMax integration, and reiterated 2026 guidance for $1.76B to $1.83B sales and $3.65 to $4.05 adjusted EPS.
6 min readGibraltar Industries (ROCK) reported Q2 net income of $8.19M, or $0.28/share, down from $26.00M, or $0.87/share a year earlier. Net sales rose 64.6% to $509.55M. Adjusted earnings from continuing operations were $1.11/share. The company reaffirmed FY26 EPS guidance of $2.40 to $2.80 and adjusted EPS of $3.65 to $4.05. ROCK was up 4.64% premarket.
3 min readGibraltar Industries (NASDAQ:ROCK) reported Q2 CY2026 revenue of $509.5 million, up 64.6% year on year, beating market expectations by 7.9%. Full-year revenue guidance of $1.80 billion at the midpoint was 1.8% above estimates. Non-GAAP EPS was $1.11, 9.1% above consensus. The stock rose 4.3% to $50.14 after results.
6 min readGibraltar Industries (ROCK) shares rose in pre-open after its Q2 2026 results beat expectations. Revenue increased 64.6% year over year to $509.5 million, and non-GAAP EPS was $1.11, about 9% above consensus. Full-year revenue guidance midpoint was $1.80 billion, slightly above analysts’ model, helped by the OmniMax acquisition and portfolio streamlining after the Renewables divestiture.
4 min readGIBRALTAR INDUSTRIES, INC. (ROCK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Gibraltar Reports Second Quarter 2026 Results Continuing Operations Net Sales +65%; with Organic Growth +5% Driven By Residential Continuing Operations EPS: GAAP $0.92, Adjusted $1.11 OmniMax integration on track; Reiterating full year 2026 guidance Buffalo, New York, August 5, 2
6 min readGibraltar Industries (NASDAQ: ROCK) is set to report earnings Wednesday before market open. Last quarter it posted revenue of $356.3 million, up 44.6% year on year, beating revenue estimates, with EPS guidance above expectations but EBITDA below. For the upcoming quarter, analysts expect revenue up 52.5% y/y. The article cites an average analyst price target of $72.50 versus $46.23.
3 min readTrident Resources (TSXV: ROCK, OTCQB: TRDTF) said it signed a July 13, 2026 option deal with Apogee Minerals to let Apogee earn 100% of Trident’s Knife Lake copper project in Saskatchewan. Apogee will pay C$400,000 cash, issue 7.4M shares plus shares valued at C$700,000, and spend C$1M on exploration over two years.
5 min readProactive’s small-cap snapshot covers ACG Metals (LSE:ACG, OTC:ACGAF), which beat its full-year oxide production target in six months, with realised gold price up 64% to $4,838/oz and first copper and zinc concentrate due in August. Rockfire Resources (LSE:ROCK) reports high zinc grades at Molaoi. Sunda Energy (AIM:SNDA) applies to explore New Zealand’s Taranaki Basin. CelLBxHealth (AIM:CLBX) targets at least £2.1m revenue. Poolbeg Pharma (AIM:POLB) raises £3.5m for trials.
4 min read
